Ser294
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser294  -  PIK4CB (human)

Site Information
SNLkRTAsNPKVENE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 457621

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 3 ) , immunoprecipitation ( 2 , 3 ) , mass spectrometry ( 4 , 5 , 6 ) , mutation of modification site ( 1 , 2 , 3 ) , phospho-antibody ( 1 , 2 , 3 ) , western blotting ( 1 , 2 , 3 )
Disease tissue studied:
breast cancer ( 4 )
Relevant cell line - cell type - tissue:
HeLa (cervical) ( 2 , 3 ) , HL-1 (myocyte) ( 1 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 4 ) , HMLER ('stem, breast cancer') ( 4 ) , myocyte-heart ( 1 ) , NCI-H1650 (pulmonary) ( 5 , 6 )

Upstream Regulation
Putative in vivo kinases:
PRKD1 (human) ( 1 )
Treatments:
C6-ceramide ( 2 ) , Go_6976 ( 2 ) , oligomycin ( 1 ) , staurosporine ( 1 )

Downstream Regulation
Effects of modification on PIK4CB:
intracellular localization ( 1 ) , molecular association, regulation ( 3 )
Induce interaction with:
ERK1 iso3 (human) ( 3 )

References 

1

Sun A, et al. (2020) Phosphatidylinositol 4-kinase IIIβ mediates contraction-induced GLUT4 translocation and shows its anti-diabetic action in cardiomyocytes. Cell Mol Life Sci
33090289   Curated Info

2

Capasso S, et al. (2017) Sphingolipid metabolic flow controls phosphoinositide turnover at the trans-Golgi network. EMBO J 36, 1736-1754
28495678   Curated Info

3

Wortzel I, et al. (2015) Mitotic Golgi translocation of ERK1c is mediated by a PI4KIIIβ-14-3-3γ shuttling complex. J Cell Sci 128, 4083-95
26459638   Curated Info

4

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

5

Possemato A (2009) CST Curation Set: 8048; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

6

Possemato A (2009) CST Curation Set: 8049; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.